Gilead Sciences' Truvada Gets FDA Priority Review - Quick Facts

Gilead Sciences To Present At UBS Global Conference; Webcast At 9:30 AM ET

Gilead Sciences To Present At Bank Of America Conference;Webcast At 12:20 PM ET

Gilead Sciences Inc. (GILD) Has Climbed To A New High On Q1 Results

Trade GILD now with

2/13/2012 7:39 PM ET

Gilead Sciences Inc. (GILD: Quote) Monday said U.S Food and Drug Administration has accepted the supplemental New Drug Application and granted a six-month priority review for once-daily Truvada to reduce the risk of HIV-1 infection among uninfected adults.

Truvada was approved by the FDA in 2004 for the treatment of HIV-1 infection and is currently the most-prescribed antiretroviral treatment in the United States.

The FDA grants priority review status to drug candidates that provide major advances in treatment or provide a treatment where no adequate therapy exists.

Truvada is not currently indicated to reduce the risk of HIV infection.

Click here to receive FREE breaking news email alerts for Gilead Sciences Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

<<Previous 94 Articles Next>>

Editors Pick

Stocks May Move Higher Ahead Of Testimony From Bernanke - U.S. Commentary

After moving modestly higher over the course of the previous session, stocks may see some further upside in early trading on Wednesday. The major index futures are currently pointing to a higher open for the markets, with the Dow futures up by 32 points.

IMF Sees Myanmar Growth At 6.7% This Fiscal

Myanmar's growth is set to accelerate slightly to 6.75 percent in the fiscal year ending March 2014 led by gas production and investment, the International Monetary Fund said on Wednesday. In an Article IV Consultation report, the IMF said Myanmar's economy grew nearly 6.5 percent in the fiscal year...

Bank Of England Split On QE; King's Stimulus Call Defeated For Fourth Month

Bank of England Chief Mervyn King maintained his call for more stimulus for the fourth month and was defeated again by a majority of six members as in previous months who cited faster-than-expected growth and pipeline impact from previous stimulus. At his penultimate meeting, King along with Paul Fisher and David Miles sought an increase in quantitative easing by GBP 25 billion.